UA73566C2 - Composition of defibrotide and haematopoietic factor used for increasing amount of stem cells and method for its preparation - Google Patents
Composition of defibrotide and haematopoietic factor used for increasing amount of stem cells and method for its preparation Download PDFInfo
- Publication number
- UA73566C2 UA73566C2 UA2002119177A UA2002119177A UA73566C2 UA 73566 C2 UA73566 C2 UA 73566C2 UA 2002119177 A UA2002119177 A UA 2002119177A UA 2002119177 A UA2002119177 A UA 2002119177A UA 73566 C2 UA73566 C2 UA 73566C2
- Authority
- UA
- Ukraine
- Prior art keywords
- hematopoietic
- defibrotide
- progenitor cells
- cells
- differs
- Prior art date
Links
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical group C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 229960004120 defibrotide Drugs 0.000 title claims abstract description 43
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 25
- 230000003394 haemopoietic effect Effects 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims description 12
- 238000002360 preparation method Methods 0.000 title claims description 3
- 210000005259 peripheral blood Anatomy 0.000 claims abstract description 14
- 239000011886 peripheral blood Substances 0.000 claims abstract description 14
- 241000124008 Mammalia Species 0.000 claims abstract description 13
- 230000002123 temporal effect Effects 0.000 claims abstract description 5
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 25
- 230000004087 circulation Effects 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 4
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 abstract description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 12
- 230000004913 activation Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000918983 Homo sapiens Neutrophil defensin 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102100039064 Interleukin-3 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102100029494 Neutrophil defensin 1 Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- -1 alkali metal salt Chemical class 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00830293A EP1147777A1 (en) | 2000-04-18 | 2000-04-18 | Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors |
| PCT/EP2001/004105 WO2001078761A2 (en) | 2000-04-18 | 2001-04-10 | Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA73566C2 true UA73566C2 (en) | 2005-08-15 |
Family
ID=8175292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002119177A UA73566C2 (en) | 2000-04-18 | 2001-10-04 | Composition of defibrotide and haematopoietic factor used for increasing amount of stem cells and method for its preparation |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20040131588A1 (bg) |
| EP (3) | EP1147777A1 (bg) |
| JP (1) | JP5205668B2 (bg) |
| KR (1) | KR100849491B1 (bg) |
| CN (1) | CN1183962C (bg) |
| AT (2) | ATE310532T1 (bg) |
| AU (2) | AU2001258322B2 (bg) |
| BG (1) | BG107203A (bg) |
| CA (1) | CA2406179C (bg) |
| CY (1) | CY1104971T1 (bg) |
| CZ (1) | CZ20023426A3 (bg) |
| DE (2) | DE60115222T2 (bg) |
| DK (2) | DK1276497T3 (bg) |
| EE (1) | EE200200596A (bg) |
| ES (2) | ES2252227T3 (bg) |
| HR (1) | HRP20020835A2 (bg) |
| HU (1) | HUP0300560A3 (bg) |
| IL (1) | IL152328A (bg) |
| IS (1) | IS2171B (bg) |
| MX (1) | MXPA02010346A (bg) |
| NO (1) | NO20024988L (bg) |
| NZ (1) | NZ522016A (bg) |
| PL (1) | PL358100A1 (bg) |
| PT (1) | PT1621207E (bg) |
| RO (1) | RO121006B1 (bg) |
| RU (1) | RU2248216C2 (bg) |
| SI (1) | SI21079B (bg) |
| SK (1) | SK14892002A3 (bg) |
| UA (1) | UA73566C2 (bg) |
| WO (1) | WO2001078761A2 (bg) |
| ZA (1) | ZA200208413B (bg) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8771663B2 (en) | 2000-04-18 | 2014-07-08 | Gentium Spa | Formulation having mobilising activity |
| EP1656156A2 (en) * | 2003-08-13 | 2006-05-17 | Children's Hospital Medical Center | Mobilization of hematopoietic cells |
| EP1656451A2 (en) | 2003-08-13 | 2006-05-17 | Children's Hospital Medical Center | Chimeric peptides for the regulation of gtpases |
| EP2103689A1 (en) * | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| RU2376985C1 (ru) * | 2008-07-17 | 2009-12-27 | Владислав Николаевич Ласкавый | Средство для активации стволовых клеток |
| WO2012063272A1 (en) | 2010-11-12 | 2012-05-18 | Gentium S.P.A. | Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd). |
| KR20150044877A (ko) | 2012-06-22 | 2015-04-27 | 젠티엄 에스피에이 | 디파이브로타이드의 생물학적 활성 측정을 위한 유우글로불린에 기초한 방법 |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| CN106567694A (zh) * | 2016-11-14 | 2017-04-19 | 北京国泰通源技术有限公司 | 智能控水短节 |
| WO2019139606A1 (en) * | 2018-01-12 | 2019-07-18 | Cellmig Biolabs Inc. | Methods for generation of cytocapsulae and cytocapsular tubes |
| WO2021095881A1 (ja) | 2019-11-13 | 2021-05-20 | 富士フイルム株式会社 | 加飾フィルム、成型物、及び電子デバイス |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899481A (en) | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| DE2154279A1 (de) | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| IT1206341B (it) | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
| US4694134A (en) | 1985-05-28 | 1987-09-15 | Ajax Magnethermic Corporation | Apparatus for overheating edges of skelp for the production of compression welded pipe |
| IT1190313B (it) | 1986-04-17 | 1988-02-16 | Crinos Industria Farmaco | Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante |
| US5223609A (en) | 1986-04-17 | 1993-06-29 | Crinos Industria Farmacobiologica S.P.A. | Process for obtaining chemically defined and reproducible polydeoxyribonucleotides |
| IT1223322B (it) * | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
| JP2907447B2 (ja) * | 1988-08-24 | 1999-06-21 | 中外製薬株式会社 | 抗血栓剤 |
| IT1231509B (it) * | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
| US5199942A (en) * | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5977083A (en) * | 1991-08-21 | 1999-11-02 | Burcoglu; Arsinur | Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states |
| JP3021906B2 (ja) * | 1992-01-28 | 2000-03-15 | 松下電器産業株式会社 | 電動調理機 |
| JPH08127539A (ja) * | 1994-10-31 | 1996-05-21 | Ajinomoto Co Inc | ヒトｉｌ−１１を含有する末梢血幹細胞増加剤 |
| US5856444A (en) * | 1994-11-30 | 1999-01-05 | Chugai Seiyaku Kabushiki Kaisha | Thrombocytopoiesis stimulating factor |
| DE69733694T2 (de) * | 1996-07-10 | 2006-07-06 | Muramatsu, Takashi, Nagoya | Verwendung von proteinen aus der mk familie als hämatopoietischer faktor |
| AU1705599A (en) * | 1997-11-26 | 1999-06-15 | Allegheny University Of The Health Sciences | Methods for mobilizing hematopoietic facilitating cells and hematopoietic stem cells into the peripheral blood |
| US6573372B2 (en) * | 1999-01-07 | 2003-06-03 | Heska Corporation | Feline immunoglobulin E molecules and compositions there of |
-
2000
- 2000-04-18 EP EP00830293A patent/EP1147777A1/en not_active Withdrawn
-
2001
- 2001-04-10 ES ES01931582T patent/ES2252227T3/es not_active Expired - Lifetime
- 2001-04-10 EP EP01931582A patent/EP1276497B1/en not_active Expired - Lifetime
- 2001-04-10 CN CNB018082025A patent/CN1183962C/zh not_active Expired - Fee Related
- 2001-04-10 DE DE60115222T patent/DE60115222T2/de not_active Expired - Lifetime
- 2001-04-10 RO ROA200201305A patent/RO121006B1/ro unknown
- 2001-04-10 EP EP05108424A patent/EP1621207B1/en not_active Expired - Lifetime
- 2001-04-10 DE DE60140015T patent/DE60140015D1/de not_active Expired - Lifetime
- 2001-04-10 ES ES05108424T patent/ES2335776T3/es not_active Expired - Lifetime
- 2001-04-10 AT AT01931582T patent/ATE310532T1/de active
- 2001-04-10 SK SK1489-2002A patent/SK14892002A3/sk unknown
- 2001-04-10 US US10/432,741 patent/US20040131588A1/en not_active Abandoned
- 2001-04-10 PL PL01358100A patent/PL358100A1/xx not_active Application Discontinuation
- 2001-04-10 AU AU2001258322A patent/AU2001258322B2/en not_active Ceased
- 2001-04-10 CZ CZ20023426A patent/CZ20023426A3/cs unknown
- 2001-04-10 WO PCT/EP2001/004105 patent/WO2001078761A2/en active IP Right Grant
- 2001-04-10 RU RU2002130719/15A patent/RU2248216C2/ru not_active IP Right Cessation
- 2001-04-10 MX MXPA02010346A patent/MXPA02010346A/es active IP Right Grant
- 2001-04-10 PT PT05108424T patent/PT1621207E/pt unknown
- 2001-04-10 AU AU5832201A patent/AU5832201A/xx active Pending
- 2001-04-10 DK DK01931582T patent/DK1276497T3/da active
- 2001-04-10 SI SI200120022A patent/SI21079B/sl not_active IP Right Cessation
- 2001-04-10 HU HU0300560A patent/HUP0300560A3/hu unknown
- 2001-04-10 KR KR1020027013967A patent/KR100849491B1/ko not_active IP Right Cessation
- 2001-04-10 NZ NZ522016A patent/NZ522016A/en unknown
- 2001-04-10 IL IL152328A patent/IL152328A/en active IP Right Grant
- 2001-04-10 AT AT05108424T patent/ATE443524T1/de active
- 2001-04-10 DK DK05108424.2T patent/DK1621207T3/da active
- 2001-04-10 JP JP2001576061A patent/JP5205668B2/ja not_active Expired - Fee Related
- 2001-04-10 EE EEP200200596A patent/EE200200596A/xx unknown
- 2001-04-10 CA CA2406179A patent/CA2406179C/en not_active Expired - Fee Related
- 2001-10-04 UA UA2002119177A patent/UA73566C2/uk unknown
-
2002
- 2002-10-14 IS IS6581A patent/IS2171B/is unknown
- 2002-10-16 NO NO20024988A patent/NO20024988L/no not_active Application Discontinuation
- 2002-10-17 ZA ZA200208413A patent/ZA200208413B/en unknown
- 2002-10-17 BG BG107203A patent/BG107203A/bg unknown
- 2002-10-18 HR HR20020835A patent/HRP20020835A2/xx not_active Application Discontinuation
-
2006
- 2006-02-08 CY CY20061100179T patent/CY1104971T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3919212B2 (ja) | 線維障害の創傷治療処置 | |
| CN101448497B (zh) | 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用 | |
| US8771663B2 (en) | Formulation having mobilising activity | |
| KR20030034177A (ko) | 허혈성 질환 치료제 | |
| UA73566C2 (en) | Composition of defibrotide and haematopoietic factor used for increasing amount of stem cells and method for its preparation | |
| US20060247265A1 (en) | Therapies for treating disorders of the eye | |
| JP2022502498A (ja) | 血液疾患の低強度治療 | |
| CN111375048A (zh) | 脾氨肽在制备治疗白细胞减少症的药物中的应用 | |
| AU2001258322A1 (en) | Formulation having mobilising activity | |
| RU2448726C2 (ru) | Содержащий g-csf агент для предупреждения и лечения диабетической периферической нейропатии | |
| US20240181010A1 (en) | Uses of il-12 as a replacement immunotherapeutic | |
| Fennelly et al. | Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial | |
| CN107737108B (zh) | 一种治疗心肌梗死后心室重塑的口服药物组合物 | |
| CN112274520A (zh) | 瑞德西韦在制备治疗特发性肺纤维化的药物中的应用 | |
| CN111249300B (zh) | 褪黑素联合甲钴胺在治疗糖尿病创面愈合障碍中的应用 | |
| WO2020010180A1 (en) | Compositions and methods for treating stroke | |
| JP2008503517A (ja) | 抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用 | |
| CN114469940B (zh) | 小分子化合物aq-390在制备抵抗细胞焦亡药物及抑制剂的应用 | |
| Colombani et al. | Harnessing the Potential of Biomaterials for COVID-19 Therapeutic Strategies | |
| JPH027293B2 (bg) | ||
| Gan et al. | Doxorubicin-associated delayed ventricular fibrillation in acute promyelocytic leukemia | |
| TWI271196B (en) | CML therapy | |
| Shishido et al. | Optimal Management of Severe Mpox in Patients with Uncontrolled HIV | |
| JPWO2020092523A5 (bg) | ||
| CN102470162A (zh) | 用于治疗难治性c型慢性肝炎的药剂以及方法 |